Watanabe T, Takahashi S, Nakajo S, Hamasaki M
Division of Nephrology, Shizuoka Children's Hospital, Japan.
Acta Paediatr Jpn. 1996 Dec;38(6):622-8. doi: 10.1111/j.1442-200x.1996.tb03720.x.
The pathological findings of 13 patients with immunoglobulin A (IgA) nephropathy or Henoch-Schönlein purpura nephritis before and after urokinase (UK) administration were investigated retrospectively. The mean activity index value decreased significantly at the time of the second biopsy compared with that of the biopsy before UK treatment. The mean chronicity index value, which was considered to reflect the renal outcome, before and after UK treatment did not change significantly, although it improved significantly in six patients. Immunofluorescence microscopy showed that the immune deposition of C3 decreased, but that of IgA and fibrin-related antigen were unchanged, by UK therapy. These results suggest that UK may prevent the mesangial proliferation associated with IgA nephropathy and Henoch-Schönlein purpura nephritis not only by its fibrinolytic action, but also by other mechanisms, such as digestion of the mesangial matrices.
回顾性研究了13例免疫球蛋白A（IgA）肾病或过敏性紫癜性肾炎患者在使用尿激酶（UK）前后的病理表现。与UK治疗前活检时相比，第二次活检时平均活动指数值显著降低。虽然6例患者的平均慢性指数值有显著改善，但UK治疗前后被认为反映肾脏转归的平均慢性指数值无显著变化。免疫荧光显微镜检查显示，UK治疗后C3的免疫沉积减少，但IgA和纤维蛋白相关抗原的免疫沉积未改变。这些结果表明，UK可能不仅通过其纤溶作用，还通过其他机制（如消化系膜基质）来预防与IgA肾病和过敏性紫癜性肾炎相关的系膜增生。
